Victor Tong
Partner @ Decheng Capital
Victor Tong is a Series A investor at Decheng Capital focused on Biotechnology and Health Care. Victor Tong
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Victor Tong invests in
Stages Victor Tong invests in
Countries Victor Tong invests in
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 3 (50%)
- Therapeutics 3 (50%)
- Medical 2 (33%)
- Life Science 1 (17%)
Stage
- Series A 2 (33%)
- Series C 2 (33%)
- Series B 1 (17%)
- Series D 1 (17%)
Country
- United States 3 (50%)
- Singapore 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cellares
|
Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M / Series D / Jan 28, 2026 | |
Aardvark Therapeutics
|
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017. | $85M / Series C / May 09, 2024 | |
|
Cellares
|
Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $255M / Series C / Aug 23, 2023 | |
Watchmaker Genomics
|
Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA. It combines deep domain expertise in protein engineering with enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth genomics applications, enabling clients to improvetheir experiment, assay, and workflow with scalable supply chain solutions that provide molecular-grade enzymes for a range of genomic applications. | $40M / Series A / Jun 02, 2022 | |
|
Cellares
|
Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $82M / Series B / May 05, 2021 | |
Hummingbird Bioscience
|
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association,including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas. | Series A / Jul 10, 2019 |
Co-Investors
Eclipse
5 deals together
8VC
2 deals together
DFJ Growth
2 deals together
ARK Investment Management
1 deal together
BlackRock
1 deal together
Bristol-Myers Squibb
1 deal together
About Decheng Capital
Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successfulcompanies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.
Decheng Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Zabrowski
Venture Partner
|
|||
Min Cui
Founder and Managing Director
|
|||
Dayton Misfeldt
Partner
|
|||
Nathan Pliam
Partner
|
|||
|
Victor Tong
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Victor Tong invest in?
Victor Tong invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Victor Tong last invest?
The most recent investment recorded for Victor Tong closed in Jan 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
